The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions

Trends in Pharmacological Sciences

Volumn 27, Issue 7, 2006, Pages 368-374

  Zeitzer, Jamie M ^a   Nishino, Seiji ^a   Mignot, Emmanuel ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMPHETAMINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; HISTAMINE H1 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIPRAMINE; IMMUNOGLOBULIN; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; NORADRENALIN UPTAKE INHIBITOR; OPIATE; OREXIN; OREXIN A; OXYBATE SODIUM; PAROXETINE; PEMOLINE; PSYCHOSTIMULANT AGENT; RECOMBINANT DNA; SERTRALINE; STEROID; THROMBIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; UROTENSIN II; VENLAFAXINE;

ABSENCE OF SIDE EFFECTS; ADRENERGIC SYSTEM; ANOREXIA; AUTOIMMUNITY; BLURRED VISION; BRAIN NERVE CELL; CATAPLEXY; CELL LOSS; CELL TRANSPLANTATION; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; DAYTIME SOMNOLENCE; DIAGNOSTIC TEST; DRUG APPROVAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; EXTENDED DRUG RELEASE; GENE THERAPY; GRAFT REJECTION; HUMAN; INTERVENTION STUDY; LATERAL HYPOTHALAMUS; LIPOPHILICITY; LIVER TOXICITY; LOW DRUG DOSE; NARCOLEPSY; NEUROBIOLOGY; NEUROLOGIC DISEASE; NIGHT; NONHUMAN; OPIATE ADDICTION; PARADOXICAL DRUG REACTION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REBOUND; REM SLEEP; REVIEW; SEXUAL DYSFUNCTION; SOMNOLENCE; TACHYCARDIA; TIMED DRUG RELEASE; TOOTH DISEASE; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

ANIMALS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES; SLEEP;

EID: 33745512663     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.05.006     Document Type: Review

References (69)

1. AASM (2005) The International Classification of Sleep Disorders, (Sateia, M.J., ed.), American Academy of Sleep Medicine
2. Reynolds III C.F., et al. Application of the multiple sleep latency test in disorders of excessive sleepiness. Electroencephalogr. Clin. Neurophysiol. 53 (1982) 443-452
3. Aldrich M.S. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 46 (1996) 393-401
4. Fukuda K., et al. High prevalence of isolated sleep paralysis: kanashibari phenomenon in Japan. Sleep 10 (1987) 279-286
5. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 50 (1998) S16-S22
6. Shepard Jr. J.W., et al. History of the development of sleep medicine in the United States. J. Clin. Sleep Med. 1 (2005) 61-82
7. España R.A., and Scammell T.E. Sleep neurobiology for the clinician. Sleep 27 (2004) 811-820
8. Pace-Schott E.F., and Hobson J.A. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat. Rev. Neurosci. 3 (2002) 591-605
9. Hishikawa Y., and Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis. Adv. Neurol. 67 (1995) 245-271
10. Von Economo C. Encephalitis Lethargica: Its Sequelae and Treatment (1931), Oxford University Press
11. Lin J.S., et al. Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat. J. Neurosci. 16 (1996) 1523-1537
12. Chou T.C., et al. Afferents to the ventrolateral preoptic nucleus. J. Neurosci. 22 (2002) 977-990
13. de Lecea L., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 322-327
14. Sakurai T., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
15. Marcus J.N., et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435 (2001) 6-25
16. Lin L., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999) 365-376
17. Hara J., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30 (2001) 345-354
18. Chemelli R.M., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 (1999) 437-451
19. Peyron C., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6 (2000) 991-997
20. Thannickal T.C., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000) 469-474
21. Nishino S., et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. 50 (2001) 381-388
22. Mignot E., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59 (2002) 1553-1562
23. Nishino S. Hypocretin measurements in the CSF, blood and brain tissues: basic to clinical applications. In: Nishino S., and Sakurai T. (Eds). The Orexin/Hypocretin System, Its Physiology and Pathophysiology (2005), Humana Press 73-82
24. Nishino S., and Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med. Rev. 9 (2005) 269-310
25. Mignot E., et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 17 (1994) S60-S67
26. Rogers A.E., et al. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 48 (1997) 1550-1556
27. Matsuki K., et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 339 (1992) 1052
28. Mignot E. Genetics of narcolepsy and other sleep disorders. Am. J. Hum. Genet. 60 (1997) 1289-1302
29. Black III J.L., et al. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep 28 (2005) 427-431
30. Black III J.L., et al. Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602. Sleep 25 (2002) 719-723
31. Dauvilliers Y., et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann. Neurol. 56 (2004) 905-908
32. Hecht M., et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 26 (2003) 809-810
33. Gerashchenko D., et al. Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. J. Neurosci. 21 (2001) 7273-7283
34. Touret M., et al. Awakening properties of modafinil without paradoxical sleep rebound: comparative study with amphetamine in the rat. Neurosci. Lett. 189 (1995) 43-46
35. Wisor J.P., et al. Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. 21 (2001) 1787-1794
36. Nishino S., et al. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res. Online 1 (1998) 49-61
37. Mochizuki T., et al. Behavioral state instability in orexin knock-out mice. J. Neurosci. 24 (2004) 6291-6300
38. Zeitzer J.M., et al. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J. Neurosci. 23 (2003) 3555-3560
39. Fujiki N., et al. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport 12 (2001) 993-997
40. Yoshida Y., et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur. J. Neurosci. 14 (2001) 1075-1081
41. Franken P., et al. Sleep homeostasis in the rat: simulation of the time course of EEG slow-wave activity. Neurosci. Lett. 130 (1991) 141-144
42. Mieda M., et al. Orexin peptides prevent cataplexy and improve wakefulness in orexin neuron-ablated model of narcolepsy in mice. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4649-4654
43. Fujiki N., and Nishino S. Hypocretin/orexin replacement therapy in hypocretin/orexin deficient narcolepsy: an overview. In: Nishino S., and Sakurai T. (Eds). The Orexin/Hypocretin System: Physiology and Pathophysiology (2005), Humana Press 367-388
44. Lang M., et al. Structure-activity studies of orexin A and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. J. Med. Chem. 47 (2004) 1153-1160
45. Asahi S., et al. Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B. Bioorg. Med. Chem. Lett. 13 (2003) 111-113
46. Darker J.G., et al. Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg. Med. Chem. Lett. 11 (2001) 737-740
47. Eriksson K.S., et al. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J. Neurosci. 21 (2001) 9273-9279
48. Nishino S., et al. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci. Lett. 313 (2001) 125-128
49. Huang Z.-L., et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9965-9970
50. Nishino, S. et al. (2002) CSF histamine content is decreased in hypocretin-deficient human narcolepsy. Sleep 25, A476-A476
51. Lin J.S. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med. Rev. 4 (2000) 471-503
52. Tedford, C.E. et al. (1999) Effects of a novel, selective, and potent histamine H3 receptor antagonist, GT-2332, on rat sleep/wakefulness and canine cataplexy. Soc. Neurosci. 25, 1134-1134
53. Shiba T., et al. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 27 (2004) A241-A242
54. Langdon N., et al. Fluoxetine in the treatment of cataplexy. Sleep 9 (1986) 371-373
55. Montplaisir J., and Godbout R. Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep 9 (1986) 280-284
56. Nishino S., and Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. 52 (1997) 27-78
57. Larrosa O., et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 24 (2001) 282-285
58. Mignot E., et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl.) 113 (1993) 76-82
59. Doherty J.D., et al. Identification of endogenous γ-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. J. Pharmacol. Exp. Ther. 207 (1978) 130-139
60. Snead III O.C., and Gibson K.M. Gamma-hydroxybutyric acid. N. Engl. J. Med. 352 (2005) 2721-2732
61. Broughton R., and Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can. J. Neurol. Sci. 6 (1979) 1-6
62. Mamelak M., et al. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 9 (1986) 285-289
63. Itzhak Y., and Ali S.F. Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB. Ann. N. Y. Acad. Sci. 965 (2002) 451-460
64. Krogsgaard-Larsen P., et al. GABA(A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Biochem. Pharmacol. 68 (2004) 1573-1580
65. Hanson L.R., et al. Intranasal administration of hypocretin-1 (orexin A) bypasses the blood-brain barrier and targets the brain: a new strategy for the treatment of narcolepsy. Drug Delivery Technology 4 (2004) 66-71
66. Fujiki N., et al. Effect of systemic and central administration of hypocretin-1 in narcoleptic (Hcrtr 2 mutated) and control dogs. Sleep 24 (2001) A96-A97
67. Hallschmid, M. et al. (2005) Intranasal administration of orexin A/hypocretin-1 in man. Orexin/Hypocretins Meeting (July 2005, Germany) 3, 25
68. Lecendreux M., et al. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J. Sleep Res. 12 (2003) 347-348
69. Chen W., et al. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann. Neurol. 58 (2005) 489-490